• In early May 2026, ICON Public Limited Company disclosed that it would miss the SEC deadline for filing its next Form 20-F, creating uncertainty around the timing of its latest audited financial information.
• At the same time, large institutional investors such as FMR LLC and Invesco Ltd. reported passive holdings each above 5% of ICON’s shares, underscoring ongoing institutional interest despite the reporting delay.
• We’ll now examine how ICON’s delayed 20-F filing, against this backdrop of institutional ownership, could affect the company’s existing investment narrative.

Find 47 companies with promising cash flow potential yet trading below their fair value.

ICON Investment Narrative Recap

To own ICON today, you have to believe its core CRO franchise and investments in AI and partnerships can offset near term noise from trial cancellations and mixed pharma demand. The delayed 20 F raises a governance and visibility question around the next audited numbers, but does not by itself alter the underlying clinical trial demand risk that already sits at the center of the story.

The most relevant recent development here is ICON’s May 2026 announcement that it will miss the SEC deadline for its 20 F filing, just as Q4 2025 results were due. Until ICON files, that delay complicates how investors assess earlier catalysts like AI enabled tools or operational efficiencies, because there is a temporary gap in the audited data used to judge whether those initiatives are translating into consistent margins and earnings.

Yet, investors should be aware that the real concern lies in how prolonged reporting uncertainty could interact with already elevated trial cancellations and...

ICON's narrative projects $8.4 billion revenue and $666.8 million earnings by 2029.

Uncover how ICON's forecasts yield a $135.07 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting ICON to reach about US$9.0 billion of revenue and roughly US$1.1 billion of earnings, but the 20 F delay and the risk of sustained trial cancellations could prompt you to question whether that upbeat view still fits, or whether your own expectations belong somewhere closer to the more cautious consensus.

Explore 5 other fair value estimates on ICON - why the stock might be worth 37% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your ICON research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free ICON research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ICON's overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 26 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.